•
Sep 30, 2020
Annexon Q3 2020 Earnings Report
Annexon reported third quarter 2020 financial results and provided a business update.
Key Takeaways
Annexon reported a net loss of $15.6 million for the third quarter of 2020. The company's cash and cash equivalents totaled $370.7 million as of September 30, 2020, bolstered by the July IPO.
Cash balance of $370.7 million as of September 30, 2020, bolstered by July IPO
Expanded ANX005 clinical program into neurodegeneration, with initiation of Phase 2 in Huntington’s Disease
Fully enrolled Phase 1b DDI trial in Guillain-Barré Syndrome
Initiated Phase 1 first-in-human trial of ANX009